Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Arbutus Biopharma Corp | exhibit321_soxcertceo2020.htm |
| EX-31.2 - EX-31.2 - Arbutus Biopharma Corp | exhibit312_10-kcertcfo2020.htm |
| EX-31.1 - EX-31.1 - Arbutus Biopharma Corp | exhibit311_10-kcertceo2020.htm |
| EX-23.1 - EX-23.1 - Arbutus Biopharma Corp | exhibit231_eyconsent2020.htm |
| EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corp | exhibit211_listingofsubsid.htm |
| EX-4.2 - EX-4.2 - Arbutus Biopharma Corp | exhibit42descriptionofsecu.htm |
| 10-K - 10-K - Arbutus Biopharma Corp | abus-20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arbutus Biopharma Corporation (the “Company”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I David Hastings, Chief Financial Officer of the Company, certify that to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company.
Date: March 4, 2021
| /s/ David Hastings | |||||||||||
| Name: | David Hastings | ||||||||||
| Title: | Chief Financial Officer | ||||||||||
| (Principal Financial Officer) | |||||||||||